124 related articles for article (PubMed ID: 8713572)
1. Cell cycle regulatory proteins are targets for induced differentiation of transformed cells: Molecular and clinical studies employing hybrid polar compounds.
Marks PA; Richon VM; Rifkind RA
Int J Hematol; 1996 Jan; 63(1):1-17. PubMed ID: 8713572
[TBL] [Abstract][Full Text] [Related]
2. Inducing differentiation of transformed cells with hybrid polar compounds: a cell cycle-dependent process.
Marks PA; Richon VM; Kiyokawa H; Rifkind RA
Proc Natl Acad Sci U S A; 1994 Oct; 91(22):10251-4. PubMed ID: 7937935
[TBL] [Abstract][Full Text] [Related]
3. Induced differentiation, the cell cycle, and the treatment of cancer.
Rifkind RA; Richon VM; Marks PA
Pharmacol Ther; 1996; 69(2):97-102. PubMed ID: 8984510
[TBL] [Abstract][Full Text] [Related]
4. Suppression of cyclin-dependent kinase 4 during induced differentiation of erythroleukemia cells.
Kiyokawa H; Richon VM; Rifkind RA; Marks PA
Mol Cell Biol; 1994 Nov; 14(11):7195-203. PubMed ID: 7935434
[TBL] [Abstract][Full Text] [Related]
5. Two cytodifferentiation agent-induced pathways, differentiation and apoptosis, are distinguished by the expression of human papillomavirus 16 E7 in human bladder carcinoma cells.
Richon VM; Russo P; Venta-Perez G; Cordon-Cardo C; Rifkind RA; Marks PA
Cancer Res; 1997 Jul; 57(13):2789-98. PubMed ID: 9205091
[TBL] [Abstract][Full Text] [Related]
6. Changes in E2F DNA-binding activity during induced erythroid differentiation.
Richon VM; Venta-Perez G
Cell Growth Differ; 1996 Jan; 7(1):31-42. PubMed ID: 8788031
[TBL] [Abstract][Full Text] [Related]
7. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.
Richon VM; Webb Y; Merger R; Sheppard T; Jursic B; Ngo L; Civoli F; Breslow R; Rifkind RA; Marks PA
Proc Natl Acad Sci U S A; 1996 Jun; 93(12):5705-8. PubMed ID: 8650156
[TBL] [Abstract][Full Text] [Related]
8. Expression and phosphorylation of the retinoblastoma protein during induced differentiation of murine erythroleukemia cells.
Richon VM; Rifkind RA; Marks PA
Cell Growth Differ; 1992 Jul; 3(7):413-20. PubMed ID: 1419904
[TBL] [Abstract][Full Text] [Related]
9. Key role of the cyclin-dependent kinase inhibitor p27kip1 for embryonal carcinoma cell survival and differentiation.
Baldassarre G; Barone MV; Belletti B; Sandomenico C; Bruni P; Spiezia S; Boccia A; Vento MT; Romano A; Pepe S; Fusco A; Viglietto G
Oncogene; 1999 Nov; 18(46):6241-51. PubMed ID: 10597222
[TBL] [Abstract][Full Text] [Related]
10. Hexamethylenebisacetamide-induced erythroleukemia cell differentiation involves modulation of events required for cell cycle progression through G1.
Kiyokawa H; Richon VM; Venta-Perez G; Rifkind RA; Marks PA
Proc Natl Acad Sci U S A; 1993 Jul; 90(14):6746-50. PubMed ID: 8341693
[TBL] [Abstract][Full Text] [Related]
11. Hexamethylene bisacetamide-induced differentiation of transformed cells: molecular and cellular effects and therapeutic application.
Marks PA; Rifkind RA
Int J Cell Cloning; 1988 Jul; 6(4):230-40. PubMed ID: 3047266
[TBL] [Abstract][Full Text] [Related]
12. Interaction of retinoblastoma protein and D cyclins during cell-growth inhibition by hexamethylenebisacetamide in TM2H mouse epithelial cells.
Said TK; Medina D
Mol Carcinog; 1998 Jun; 22(2):128-43. PubMed ID: 9655257
[TBL] [Abstract][Full Text] [Related]
13. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.
Richon VM; Emiliani S; Verdin E; Webb Y; Breslow R; Rifkind RA; Marks PA
Proc Natl Acad Sci U S A; 1998 Mar; 95(6):3003-7. PubMed ID: 9501205
[TBL] [Abstract][Full Text] [Related]
14. Structural characterization of erythroid and megakaryocytic differentiation in Friend erythroleukemia cells.
Hyman T; Rothmann C; Heller A; Malik Z; Salzberg S
Exp Hematol; 2001 May; 29(5):563-71. PubMed ID: 11376868
[TBL] [Abstract][Full Text] [Related]
15. Changes in p34cdc2 kinase activity and cyclin A during induced differentiation of murine erythroleukemia cells.
Kiyokawa H; Ngo L; Kurosaki T; Rifkind RA; Marks PA
Cell Growth Differ; 1992 Jun; 3(6):377-83. PubMed ID: 1419901
[TBL] [Abstract][Full Text] [Related]
16. Induced differentiation of murine erythroleukemia cells (MELC) by polar compounds: marked increased sensitivity of vincristine resistant MELC.
Marks PA; Michaeli J; Jackson J; Richon VM; Rifkind RA
Prog Clin Biol Res; 1989; 316B():171-81. PubMed ID: 2616574
[TBL] [Abstract][Full Text] [Related]
17. Induced differentiation of erythroleukemia cells by hexamethylene bisacetamide: a model for cytodifferentiation of transformed cells.
Marks PA; Rifkind RA
Environ Health Perspect; 1989 Mar; 80():181-8. PubMed ID: 2647479
[TBL] [Abstract][Full Text] [Related]
18. Changes in E2F complexes containing retinoblastoma protein family members and increased cyclin-dependent kinase inhibitor activities during terminal differentiation of cardiomyocytes.
Flink IL; Oana S; Maitra N; Bahl JJ; Morkin E
J Mol Cell Cardiol; 1998 Mar; 30(3):563-78. PubMed ID: 9515032
[TBL] [Abstract][Full Text] [Related]
19. Polar/apolar chemical inducers of differentiation of transformed cells: strategies to improve therapeutic potential.
Marks PA; Breslow R; Rifkind RA; Ngo L; Singh R
Proc Natl Acad Sci U S A; 1989 Aug; 86(16):6358-62. PubMed ID: 2762329
[TBL] [Abstract][Full Text] [Related]
20. Combination cytotoxic-differentiation therapy of mouse erythroleukemia cells with 5-fluorouracil and hexamethylene bisacetamide.
Waxman S; Scher BM; Hellinger N; Scher W
Cancer Res; 1990 Jul; 50(13):3878-87. PubMed ID: 2354439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
